@scienceofpd.bsky.socialNew research finds administration of the fatty acid nitroalkene 10-nitro-octadec-9-enoic acid (10-NO2-OA) in a chronic rotenone rat model of #Parkinsons induced biochemical responses that reduced neuronal damage, nigrostriatal degen. & motor impairment
www.nature.com/articles/s41...
@scienceofpd.bsky.socialNew clinical trial registered: The Vista PD study is a 12 week randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, & tolerability of VIM0423 (muscarinic cholinergic receptor antagonist) in 80 people with #Parkinsons
clinicaltrials.gov/study/NCT078...
@scienceofpd.bsky.socialNew clinical trial registered: The ARREST-PD study is a 72-week multicenter, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the disease-modifying efficacy of Sitagliptin therapy in 160 people with early-stage #Parkinsons
clinicaltrials.gov/study/NCT078...
@scienceofpd.bsky.socialOver the 50-day study, PK analysis showed brain penetrance & dose-dependent exposure; Results support weekly dosing; Clear trends seen for biomarker movement; Majority of #Parkinsons patients who received TT-P34 showed a coordinated response across lysosomal proteins in CSF
@scienceofpd.bsky.socialLooking forward to the @cureparkinsons.org.uk Autumn Research Update meeting on "How neurotrophic factors could be used to treat #Parkinsons". It will be at the Royal Society of Medicine on Monday 19th October
cureparkinsons.org.uk/2026/09/autu...
@scienceofpd.bsky.socialTeitur Trophics announces successful results from their Phase I clinical trial of first-in-class #Parkinsons peptide TT-P34; They are planning to start a Phase 2 testing in PD in 2027
www.teiturtrophics.com/news
@uhnresearch.ca1/ Why does deep brain stimulation (DBS) affect people with #Parkinsons differently?
Researchers at @kbi-uhn.bsky.social found that DBS affects brain-wide networks and that outcomes differ across two common targets. The findings could help personalize care.
@molneurodegen.bsky.social#Retromer-targeted #therapy for neurodegenerative diseases
Michele Persico...Simona Eleuteri, David K. Simon @harvardmed.bsky.social #AlzheimersDisease #Parkinsons #AmyotrophicLateralSclerosis
@aussmc.bsky.social🚬EXPERT REACTION: Why is smoking linked to a lower risk of Parkinson's?
🗨️ @latrobe.edu.au @griffith.edu.au and @westernsydneyu.bsky.social experts respond to the research
@scienceofpd.bsky.socialNew research finds the G2019S mutation modulates the neuroimmune response in transgenic mice, but does not exacerbate nigrostriatal neurodegeneration in response to mitochondrial dysfunction, highlighting the mutation's complex role in #Parkinsons path.
onlinelibrary.wiley.com/doi/10.1111/...
@scienceofpd.bsky.socialNew study finds α-syn. clearance & propagation are mediated by glymphatic function; Aquaporin-4 mis-localization observed in the presence of human synucleinopathy may contribute to the dev. & propagation of Lewy body path. in conditions like #Parkinsons
academic.oup.com/braincomms/a...
@mwise1.bsky.socialWarms my heart! 💙 "So…Your Friend Has Parkinson’s”: Michael J. Fox and Harrison Ford Star in New Video for The Michael J. Fox Foundation’s Latest Brand Awareness Campaign
[Video & Story Link] www.michaeljfox.org/news/soyour-...
@scienceofpd.bsky.socialNew research reveals "a dual-gradient architecture that reflects the functional heterogeneity of the substantia nigra & offers new markers, grounded in behav. & pathol., for stratifying neurodegen. disease risk in aging, #Parkinsons & #Alzheimers"
www.nature.com/articles/s41...
@aging-us.bsky.social🔆 #PaperSpotlight:
A new #Research paper was published on August 13, titled “Protective effects of three herbal extracts on mitochondrial dysfunction in VPS13C-knockdown SH-SY5Y cells: implications for Parkinson’s disease.”
@aging-us.bsky.social🎧 Listen to our #PressRelease on the #Research paper, "Protective effects of three herbal extracts on mitochondrial dysfunction in VPS13C-knockdown SH-SY5Y cells: implications for Parkinson’s disease."
@scienceofpd.bsky.social"Extremely high rates of co-pathologies suggest that therapeutics focused on a singular pathology are perhaps not very likely to be successful in modifying the course of #Parkinsons b/c they are only treating a small fraction of the disease pathobiology"
journals.sagepub.com/doi/10.1177/...
@scienceofpd.bsky.socialFurther research on the detection of α-synuclein seeding activity in tear fluid, suggesting it as a candidate biomarker for #Parkinsons
journals.sagepub.com/doi/10.1177/...
@scienceofpd.bsky.socialCombination therapies! Scientists report the neuroprotective effects of empagliflozin & metformin combined therapy in a rotenone model of #Parkinsons; "restoration of PI3K/AKT signaling, ⬆️of PPAR-γ expression, &🫸of oxidative stress & protein aggregation"
@scienceofpd.bsky.socialInteresting development - one to watch: Andarta Therapeutics has obtained rights to advance Teva's fatty acid synthase (FASN) inhibitor program to develop innovative treatments for #Parkinsons with support via a grant from the Michael J Fox Foundation
www.andartatx.com/articles/agr...
@scienceofpd.bsky.socialHere is another from Dimitri Krainc: "As we celebrate Michael’s Lasker Award, we honor a humanitarian whose compassion has touched countless lives, & a leader whose vision continues to reshape the future of #Parkinsons research"
www.jci.org/articles/vie...